{"id":"W4319922981","doi":"10.1016/j.ejca.2023.02.002","title":"Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Chugai Pharmaceutical; PharmaMar; Daiichi Sankyo Europe; Servier; Sanofi; Kyowa Hakko Kirin; Astellas Pharma; Eisai; Genomic Health; Fondation ARC pour la Recherche sur le Cancer; Seagen; Genentech; Veracyte; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Medpace; Puma Biotechnology; Regeneron Pharmaceuticals; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; Kræftens Bekæmpelse; European Commission; Exelixis; Amgen; Pfizer; Celgene","keywords":"Neratinib; Trastuzumab; Medicine; Placebo; Oncology; Breast cancer; Internal medicine; Pertuzumab; Adjuvant; Adjuvant therapy; Double blind; Cancer; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020067,0.002107585,0.004335508,0.0004078523,0.0004150936,0.001230381,0.001099972,0.002098356,0.0063042],"category_scores_gemma":[0.001645345,0.0005984075,0.002705888,0.0004423618,0.00143225,0.001685135,0.0005364924,0.00368421,0.001114309],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006701819,"about_ca_system_score_gemma":0.0007507066,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006946847,"about_ca_topic_score_gemma":0.00146934,"domain_scores_codex":[0.9993638,0.0003180602,0.00003963852,0.0001264806,0.00003691089,0.0001149826],"domain_scores_gemma":[0.9993289,0.0001967916,0.0001403185,0.00007303426,0.00003692051,0.0002240497],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9878109,0.001729623,0.0002143921,0.0005197874,0.0006728717,0.00002581357,0.0000278704,0.0002658686,0.001173321,0.00007592726,0.0004675393,0.007016036],"study_design_scores_gemma":[0.9715061,0.02659159,0.0007179138,0.00002491037,0.0003316395,0.00002524141,0.00001361972,0.0001859429,0.0001694988,0.0001194454,0.0003025584,0.0000114851],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845841,0.007760743,0.0007781747,0.0007488516,0.0009077694,0.002007054,0.001088207,0.0001917981,0.001933456],"genre_scores_gemma":[0.983467,0.00448049,0.001125643,0.001135255,0.0005200044,0.002880502,0.001511266,0.00004630547,0.004833489],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0063042,"threshold_uncertainty_score":0.02108967,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0521616362129542,"score_gpt":0.3818282319083606,"score_spread":0.3296665956954064,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}